CAS 141505-33-1|Levosimendan
| Common Name | Levosimendan | ||
|---|---|---|---|
| CAS Number | 141505-33-1 | Molecular Weight | 280.285 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C14H12N6O | Melting Point | 216-219ºC (dec.) |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | levosimendan |
|---|---|
| Synonym | More Synonyms |
Levosimendan BiologicalActivity
| Description | Levosimendan(OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.Target: OthersLevosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy [1]. The cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators [2]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients [3]. |
|---|---|
| Related Catalog | Signaling Pathways >>Autophagy >>AutophagyResearch Areas >>Cardiovascular Disease |
| References | [1]. Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245. [2]. Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7. [3]. Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Melting Point | 216-219ºC (dec.) |
| Molecular Formula | C14H12N6O |
| Molecular Weight | 280.285 |
| Exact Mass | 280.107269 |
| PSA | 113.43000 |
| LogP | 0.59 |
| Index of Refraction | 1.673 |
| InChIKey | WHXMKTBCFHIYNQ-SECBINFHSA-N |
| SMILES | CC1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H312-H332 |
| Precautionary Statements | P280 |
| Hazard Codes | Xn |
| Risk Phrases | R20/21/22 |
| Safety Phrases | S36/S37 |
| RIDADR | NONH for all modes of transport |
| RTECS | TY1570210 |
Articles22
More Articles| Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. Thromb. Haemost. 113(2) , 350-62, (2015) Levosimendan is a positive inotropic drug for the treatment of acute decompensated heart failure (HF). Clinical trials showed that levosimendan was particularly effective in HF due to myocardial infar... | |
| Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene. Skelet. Muscle 5 , 12, (2015) Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is characterized by generalized skeletal muscle weakness, often from birth. To date, no therapy exists that enhances the con... | |
| A Bayesian network meta-analysis on the effect of inodilatory agents on mortality. Br. J. Anaesth. 114 , 746-56, (2015) Inodilators are commonly used in critically ill patients, but their effect on survival has not been properly studied to date. The objective of this work was to conduct a network meta-analysis on the e... |
Synonyms
| Levosimedan |
| Mesoxalonitrile (-)-[p-[(R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazone |
| ({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)malononitrile |
| ({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridazinyl]phenyl}hydrazono)malononitrile |
| (R)-[[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile |
| Propanedinitrile, 2-[2-[4-[(4R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]- |
| Levosimendan |
| (R)-(-)-2-[4-(4-methyl-6-oxo-1,4,5,6,-tetrahydropyridazin-3-yl)phenylhydrazono]propanedinitrile |
| MFCD00867135 |
| Simdax |
| (2-{4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazinyliden)propandinitril |
| 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile |
| (R)-Simendan |
